[Federal Register Volume 65, Number 159 (Wednesday, August 16, 2000)]
[Notices]
[Pages 49991-49992]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-20722]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Advisory Committees; Industry Representation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing its 
intention of adding one nonvoting representative of industry interests 
to the membership of its existing advisory committees that do not 
already have such nonvoting industry representation under the purview 
of the Center for Biologics Evaluation and Research

[[Page 49992]]

(CBER) and the Center for Drug Evaluation and Research (CDER). 
Elsewhere in this issue of the Federal Register, FDA is publishing a 
notice to request nominations for nonvoting members of industry 
interests on public advisory committees.

FOR FURTHER INFORMATION CONTACT: Donna M. Combs, Committee Management 
Office (HFA-306), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-827-5496.

SUPPLEMENTARY INFORMATION: Section 120 of the FDA Modernization Act 
(FDAMA) of 1997 (21 U.S.C. 355) requires that certain newly formed FDA 
advisory committees include representatives from the biologics and/or 
drug manufacturing industries. Although not required for existing 
committees, the agency intends to add nonvoting industry 
representatives to all its CBER and CDER advisory committees.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.

    Dated: August 7, 2000.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 00-20722 Filed 8-15-00; 8:45 am]
BILLING CODE 4160-01-F